Show simple item record

dc.contributor.authorHarrington, Jenniferen
dc.contributor.authorCarter, Louiseen
dc.contributor.authorBasu, Bristien
dc.contributor.authorCook, Natalieen
dc.date.accessioned2018-12-14T10:37:19Z
dc.date.available2018-12-14T10:37:19Z
dc.identifier.issn0147-0272
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/286966
dc.description.abstractAbstract Pancreatico-biliary tumours arise from the pancreas, bile duct and Ampulla of Vater. Despite their close anatomical location, they have different aetiology and biology. However, they uniformly share a poor prognosis, with no major improvements observed in overall survival over decades, even in the face of progress in diagnostic imaging, surgical techniques and advances in systemic and loco-regional radiation therapies. To date, cytotoxic treatment has been associated with modest benefits in the advanced disease setting, and survival for patients with stage IV disease has not exceeded a year. Therefore, there is a pressing need to identify better treatments which may impact more significantly. Frequently, encouraging signals of potential efficacy for novel agents in early phase clinical trials have been followed by disappointing failures in larger Phase III trials , raising the valid question of how drug development can be optimised for patients with pancreatic adenocarcinoma and biliary tract malignancies (P-B tumours). In this paper we summarise the current therapeutic options for these patients and their limitations. The biological context of these cancers is reviewed, highlighting features that may make them resistant to standard chemotherapeutics and could be potential therapeutic targets. We will discuss the role of early phase clinical trials, defined as Phase I and non-randomised Phase 2 trials, within the clinical context and current therapeutic landscape of P-B tumours and postulate how translational studies and trial design may enable better realisation of emerging targets together with a proposed model for future patient management. A detailed summary of current Phase I clinical trials in P-B tumours is provided.
dc.publisherElsevier
dc.titleDrug Development and Clinical Trial Design in Pancreatico-biliary malignanciesen
dc.typeArticle
prism.endingPage94
prism.issueIdentifier1en
prism.publicationNameCurrent Problems in Canceren
prism.startingPage73
prism.volume42en
dc.identifier.doi10.17863/CAM.34275
dcterms.dateAccepted2018-01-04en
rioxxterms.versionofrecord10.1016/j.currproblcancer.2018.01.003en
rioxxterms.versionAM*
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/en
rioxxterms.licenseref.startdate2018-01-04en
dc.contributor.orcidBasu, Bristi [0000-0002-3562-2868]
dc.identifier.eissn1535-6345
rioxxterms.typeJournal Article/Reviewen
cam.issuedOnline2018-01-08en
dc.identifier.urlhttps://www.sciencedirect.com/science/article/pii/S0147027217301575?via=ihuben
datacite.issupplementedby.doi10.1016/j.currproblcancer.2018.01.003en
rioxxterms.freetoread.startdate2019-01-08


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record